Novonesis AS

Transaction in Own Shares • Oct 29, 2012

October 29, 2012

Termination of share buyback program

On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission (EC) Regulation No 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation.

The share buyback program was announced in connection with Novozymes' first-half results on August 11, 2011. The program covers an amount of up to DKK 2 billion over a two-year period, starting in 2012, and is contingent upon no major acquisitions being made.

With the announcement today of the strategic partnership with and acquisition of a share in Beta Renewables (Company announcement No. 68), the aforementioned share buyback program is hereby terminated.

All of the shares purchased under the program will be cancelled, subject to approval at the Annual Shareholders' Meeting on February 28, 2013, as previously announced. A new decision by the Board of Directors is required if Novozymes is to initiate a new share buyback program.

The following transactions have been carried out under the program:

	Number of	Average purchase	Transaction value,
	shares	price	DKK
Accumulated, last announcement	5,234,731	160.63	829,782,120
October 26, 2012	12,857		2,065,214
Accumulated under the program	5,247,588		831,847,334

Since Company announcement No. 67, 2012 on October 26, 2012, Novozymes has not sold any shares relating to Novozymes' incentive programs. The transactions related to the incentive programs are not part of the Safe Harbour share buyback program.

Including the transactions stated above, Novozymes owns a total of 12,900,286 shares of treasury stock, corresponding to 4.0% of the common stock on October 26, 2012. The total number of shares in the company is 325,000,000, including treasury stock.

Contact persons: Press and media: Investor relations: René Tronborg (Europe) Tel. (direct): +45 4446 2274 Tel. (mobile): +45 3077 2274

Paige Donnelly (USA) Tel. (direct): +1 919 494 3209 Tel. (mobile): +1 919 218 4501 Maarit Pokkinen Tel. (direct): +45 4446 8682 Tel. (mobile): +45 3077 8682

Martin Riise Tel. (direct): +45 4446 0738 Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA) Tel. (direct): +1 919 494 3483 Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.